ArticleChemical engineering journal (Lausanne, Switzerland : 1996)2023
Controlled Lipid Self-Assembly for Scalable Manufacturing of Next-Generation Immune Stimulating Complexes.
Article in Chemical engineering journal (Lausanne, Switzerland : 1996), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Harnessing biofilm colonizers: alleviate light limitation and boost nutrients removal via phosphorus-accumulating and photo-related microbes.Bioprocess and biosystems engineering · 2026Article
- Targeting cuproptosis opens a new chapter of nanomedicine: a scientometric and graphical analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Scale-up and cGMP manufacturing of next-generation vaccine adjuvant saponin/MPLA nanoParticles (SMNP).Journal of pharmaceutical sciences · 2025Article
- Nano/Micro-Enabled Modification and Innovation of Conventional Adjuvants for Next-Generation Vaccines.Journal of functional biomaterials · 2025Review
- The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.The Journal of clinical investigation · 2025Article
- Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Surfactant-Mediated Assembly of Precision-Size Liposomes.Chemistry of materials : a publication of the American Chemical Society · 2024Article
- Determination of low concentrations of glucose through colorimetric analysis using CoFeAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Engineering customized nanovaccines for enhanced cancer immunotherapy.Bioactive materials · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Immune stimulating complexes (ISCOMs) are safe and effective saponin-based adjuvants formed by the self-assembly of saponin, cholesterol, and phospholipids in water to form cage-like 30-40 nm diameter particles. Inclusion of the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) in ISCOM particles yields a promising next-generation adjuvant termed Saponin-MPLA NanoParticles (SMNP). In this work, we detail protocols to produce ISCOMs or SMNP via a tangential flow filtration (TFF) process suitable for scalable synthesis and Good Manufacturing Practice (GMP) production of clinical-grade adjuvants. SMNP or ISCOM components were solubilized in micelles of the surfactant MEGA-10, then diluted below the critical micelle concentration (CMC) of the surfactant to drive ISCOM self-assembly. Assembly of ISCOM/SMNP particles using the purified saponin QS-21 used in clinical-grade saponin adjuvants was found to require controlled stepwise dilution of the initial micellar solution, to prevent formation of undesirable kinetically-trapped aggregate species. An optimized protocol gave yields of ~77% based on the initial feed of QS-21 and the final SMNP particle composition mirrored the feed ratios of the components. Further, samples were highly homogeneous with comparable quality to that of material prepared at lab scale by dialysis and purified via size-exclusion chromatography. This protocol may be useful for clinical preparation of ISCOM-based vaccine adjuvants and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.